Medibio Limited: Mayo Clinic to begin Prospective Clinical Study with Medibio Technology for Expanded Market Opportunities

-- Study designed to determine differential diagnosis in depression patients
  -- Study designed to monitor patient data following pharmacological treatment

SYDNEY, Australia and MINNEAPOLIS, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Medibio
Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health
technology company that has pioneered the use of objective biometrics to assist
in the screening, diagnosing, monitoring and management of depression and other
mental health conditions,  is pleased to announce the first prospective
clinical trial with Mayo Clinic under a 5-year Master Clinical Trial Agreement
that was signed in October of this year.  This initial study, undertakes the
prospective diagnosis and longitudinal monitoring of both unipolar and bipolar
depression, along with the depressive subtypes (melancholic and atypical). 

The primary goal is to characterize longitudinal autonomic, circadian, and
sleep patterns, as classified by the Medibio Analytics Platform (MAP),
following the initiation of a standard pharmacological treatment for a new or
recurrent, moderate-to-severe major depressive episode of both the unipolar and
bipolar type.  Additionally, MAP will be used to characterize patterns unique
to the bipolar type depression. 

The research study team will be led by Mark A. Frye, M.D., at Mayo Clinic's
Rochester campus. Dr. Frye, the chair of Mayo's Department of Psychiatry and
Psychology, received his medical degree from the University of Minnesota and
completed his psychiatric training at the UCLA Neuropsychiatric Institute. He
completed a subsequent research fellowship in the Biological Psychiatry Branch
at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While
at NIMH, his area of research was focusing on the neurobiology of depression
and bipolar disorder. 

"We have been eager to get this initial study started with Dr. Frye and Mayo
Clinic, as this kicks off our first of many collaborations in mental health
between our organizations.  The importance of this study is to look at bipolar
depression and differential diagnosis with our analytics platform, which can
ultimately drive getting the right treatment to the right patient at the right
time.  Mayo remains a leading academic center of excellence that the world
looks to for innovative solutions to global problems," says Jack Cosentino,
Medibio's CEO and Managing Director. 

"The Mayo Clinic Depression Center has focused our research efforts on studies
that have the potential to innovate our clinical practice; making a positive
impact on patients' lives," says Dr. Frye. 

It is estimated that 350M people worldwide suffer from depression. Depression
is one of the leading causes of disability in the United States.  Two major
challenges in the clinical practice of mood disorder is distinguishing major
depressive disorder from bipolar depression and individualizing treatments for
patients who struggle with depression. As treatment options markedly differ in
these two mood disorders, biomarkers to help accurate diagnosis and guide
treatment would be of tremendous clinical value. 

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has
pioneered the use of objective biometrics to assist in the screening,
diagnosing, monitoring and management of depression and other mental health
conditions. The company was founded in Australia, with offices located in
Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the
Australian Securities Exchange Ltd and trades on the OTCQB Venture Market.
Investors can find additional information on www.otcmarkets.com and
www.asx.com.au. 

Further Information: Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director
Medibio Limited
[e-mail]
T: [phone]

Australian Media Enquiries:
Peter Taylor
NWR Communications
[e-mail]
T: [phone]